R&D Capability
We have established multi-level, multi-channel and fruitful communication and cooperation with a number of domestic scientific research institutions and universities.
We have also undertaken Industry-Academia-Research-Medicine project of STCSM: Post-marketing clinical re-evaluation study of oncolytic virus anti-tumor drug Oncorine.

With reference to the results of basic and clinical research on oncolytic viruses in the field of antitumor therapy in recent years and combining actual clinical work experience, dozens of experts in the field of basic and clinical research on tumor bioimmunotherapy in Shanghai, prepared the Shanghai Experts Consensus on the clinical application of oncolytic viruses in the treatment of malignant tumors from the aspects of classification of oncolytic viruses antitumor mechanism, EBM of clinical application, usage, management of adverse reactions and evaluation of efficacy. As the world's first marketed oncolytic adenovirus drug, the consensus described the clinical use and efficacy observation of Oncorine in detail.

1150 Guiqiao Road.,China (Shanghai) Pilot Free Trade Zone

sunwaybio@sunwaybio.com.cn

(+86) 021-50310270

Company Wechat

Shanghai Sunway Biotech Co., Ltd.©All rights reserved.

(沪)-非经营性-2017-0090 沪ICP备05059751号-1

Legal Statement